Impact of Rapid Molecular Diagnostics on Vancomycin-Resistant Enterococcal Bacteremia Outcomes

Overview

Rapid molecular diagnostic testing (RMDT) for vancomycin-resistant enterococci (VRE) bacteremia significantly reduced the time to active antimicrobial therapy from 32 to 21 hours. However, no overall mortality benefit was observed, although a subgroup without leukemia showed decreased 30-day mortality that was not sustained in multivariate analysis.

Background

Vancomycin-resistant enterococci bacteremia is a serious infection with high mortality rates ranging from 33.7% to 50.5%. Delays in appropriate antimicrobial therapy beyond 48 hours are associated with increased mortality. Rapid molecular diagnostic tests can detect VRE and vancomycin resistance genes within hours of blood culture positivity, potentially enabling earlier targeted therapy. Despite this, prior studies have shown mixed results regarding the impact of RMDT on clinical outcomes.

Data Highlights

Key Findings

• RMDT implementation reduced median time to active antimicrobial therapy by 11 hours (21 vs 32 hours; P < .001).
• No statistically significant difference in overall 30-day mortality between RMDT and non-RMDT groups (31.6% vs 36.5%; P = .230).
• Subgroup analysis excluding leukemia patients showed decreased 30-day mortality with RMDT (29.6% vs 40.8%; P = .037), but this was not confirmed on multivariate analysis.
• RMDT detected Enterococcus species and vanA/B resistance genes directly from positive blood cultures within 2–3 hours, earlier than conventional susceptibility testing.
• Antimicrobial stewardship programs and institutional guidelines accompanied RMDT implementation but did not change during the study period.

Clinical Implications

Rapid molecular diagnostic testing can facilitate earlier initiation of effective antimicrobial therapy in patients with VRE bacteremia, potentially improving management efficiency. However, clinicians should be aware that earlier detection and treatment have not consistently translated into improved mortality outcomes. Continued integration with antimicrobial stewardship and clinical judgment remains essential.

Conclusion

RMDT for VRE bacteremia significantly shortens time to appropriate therapy but does not clearly improve mortality outcomes. Further research is needed to identify patient subgroups that may benefit clinically from rapid diagnostics.

References

1. CDC 2019 -- Antibiotic Resistance Threats in the United States
2. Weiner et al. 2016 -- Antimicrobial-Resistant Pathogens in Healthcare
3. Kamboj et al. 2017 -- Impact of Rapid Molecular Testing on VRE Bacteremia